EUVIMEDEUVIMED entdecken
Open Access

DNA methylation profiling of pituitary neuroendocrine tumors identifies distinct clinical and pathological subtypes based on epigenetic differentiation

Sarra Belakhoua iD, Varshini Vasudevaraja, Chanel Schroff, Kristyn Galbraith, Misha Movahed-Ezazi iD, Jonathan Serrano iD, Yiying Yang, Daniel Orringer, John G Golfinos iD, Chandra Sen, Donato Pacione, Nidhi Agrawal iD und 1 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Sarra Belakhoua und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, New York 10016, USA. Hauptthemen laut MEDLINE: DNA Methylation, Pituitary Neoplasms, Neuroendocrine Tumors, Epigenesis, Genetic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NINDS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pituitary neuroendocrine tumors (PitNETs) are the most common intracranial neuroendocrine tumors. PitNETs can be challenging to classify, and current recommendations include a large immunohistochemical panel to differentiate among 14 WHO-recognized categories.

Methods

In this study, we analyzed clinical, immunohistochemical, and DNA methylation data of 118 PitNETs to develop a clinicomolecular approach to classifying PitNETs and identifying epigenetic classes.

Results

CNS DNA methylation classifier has an excellent performance in recognizing PitNETs and distinguishing the 3 lineages when the calibrated score is ≥ 0.3. Unsupervised DNA methylation analysis separated PitNETs into 2 major clusters. The first was composed of silent gonadotrophs, which form a biologically distinct group of PitNETs characterized by clinical silencing, weak hormonal expression on immunohistochemistry, and simple copy number profile. The second major cluster was composed of corticotrophs and Pit1 lineage PitNETs, which could be further classified using DNA methylation into distinct subclusters that corresponded to clinically functioning and silent tumors and are consistent with transcription factor expression. Analysis of promoter methylation patterns correlated with lineage for corticotrophs and Pit1 lineage subtypes. However, the gonadotrophic genes did not show a distinct promoter methylation pattern in gonadotroph tumors compared to other lineages. Promoter of the NR5A1 gene, which encodes SF1, was hypermethylated across all PitNETs clinical and molecular subtypes including gonadotrophs with strong SF1 protein expression indicating alternative epigenetic regulation.

Conclusion

Our findings suggest that classification of PitNETs may benefit from DNA methylation for clinicopathological stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationPituitary NeoplasmsNeuroendocrine TumorsEpigenesis, GeneticBiomarkers, TumorHumansFemaleMaleMiddle AgedAdultPromoter Regions, GeneticAgedPrognosisYoung Adult

Stichwörter der Autor:innen

DNA methylationpituitary neuroendocrine tumorspromoter methylationunsupervised hierarchical clustering

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, New York 10016, USA.
  • Department of Neurosurgery, NYU Grossman School of Medicine, NYU Langone Health, New York, New York 10016, USA.
  • Department of Medicine, NYU Grossman School of Medicine, NYU Langone Health, New York, New York 10016, USA.
  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York 10016, USA.

ORCID-Profile: Sarra Belakhoua, Misha Movahed-Ezazi, Jonathan Serrano, John G Golfinos, Nidhi Agrawal, Matija Snuderl

Förderung

  • NIH HHS
  • NINDS NIH HHS
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Belakhoua, S., Vasudevaraja, V., Schroff, C., Galbraith, K., Movahed-Ezazi, M., Serrano, J., Yang, Y., Orringer, D., Golfinos, J. G., Sen, C., Pacione, D., Agrawal, N., & Snuderl, M. (2025). DNA methylation profiling of pituitary neuroendocrine tumors identifies distinct clinical and pathological subtypes based on epigenetic differentiation. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf109

Vancouver

Belakhoua S, Vasudevaraja V, Schroff C, Galbraith K, Movahed-Ezazi M, Serrano J, et al. DNA methylation profiling of pituitary neuroendocrine tumors identifies distinct clinical and pathological subtypes based on epigenetic differentiation. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf109

BibTeX
@article{Belakhoua2025,
  author = {Belakhoua, Sarra and Vasudevaraja, Varshini and Schroff, Chanel and Galbraith, Kristyn and Movahed-Ezazi, Misha and Serrano, Jonathan and Yang, Yiying and Orringer, Daniel and Golfinos, John G and Sen, Chandra and Pacione, Donato and Agrawal, Nidhi and Snuderl, Matija},
  title = {DNA methylation profiling of pituitary neuroendocrine tumors identifies distinct clinical and pathological subtypes based on epigenetic differentiation},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf109}
}
Kostenlos starten →